Examining how different BRCA1/2 gene variants affect ovarian cancer treatment and outcomes
Impatto Delle Diverse Varianti Dei Geni BRCA1/2 su Risposta Alla Terapia e Prognosi Del Carcinoma Ovarico
This study is testing how different changes in the BRCA1 and BRCA2 genes affect treatment responses and survival in ovarian cancer patients to help tailor more effective therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Sex | Female |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06775470 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify significant differences in drug response and survival rates among ovarian cancer patients with various BRCA1 and BRCA2 gene alterations. By analyzing these genetic variants, the study seeks to stratify patients for more personalized and effective therapies, particularly focusing on the efficacy of PARP inhibitors. The research will involve patients diagnosed with ovarian cancer who have undergone BRCA testing at a specific medical center. The goal is to enhance treatment strategies based on genetic profiles.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with ovarian cancer who are BRCA positive and have undergone BRCA testing.
Not a fit: Patients with mucinous or borderline histotype ovarian carcinoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for ovarian cancer patients based on their specific BRCA gene variants.
How similar studies have performed: Other studies have shown success in using genetic profiling to tailor cancer therapies, indicating a promising approach for this research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ovarian cancer diagnosis by 31/12/2021; * BRCA test at the UOC of Medical Genetics of the IRCCS AOU of Bologna Policlinico S.Orsola by 31/12/2021; * follow-up and/or treatment at Medical Oncology and/or Gynaecological Oncology of the IRCCS Azienda Ospedaliero-Universitaria (AOU) of Bologna for a period of time of at least 1 year and by 31/12/2021 and for a minimum period of 6 months Exclusion Criteria: * ovarian carcinoma of 'mucinous' or 'borderline' histotype.
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola — Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Daniela Turchetti, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
- Study coordinator: Daniela Turchetti, MD
- Email: daniela.turchetti@unibo.it
- Phone: +390512143694
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.